Key roles of necroptotic factors in promoting tumor growth

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Necroptotic factors are typically considered beneficial in cancer therapy for eliminating tumor cells.
• However, their precise role in tumor progression remains incompletely understood.

Purpose of the Study:

• To investigate the role of necroptotic factors (RIPK1, RIPK3, MLKL) in tumor growth and their potential as therapeutic targets.
• To explore the mechanism by which necroptotic factors influence tumor progression, specifically NF-κB activity.

Main Methods:

• Genetic knockout of RIPK1, RIPK3, and MLKL in cancer cells.
• Assessing anchorage-independent growth and radiosensitivity of knockout cells.
• Evaluating tumor formation in mouse xenograft models using knockout cells and a necroptosis inhibitor (NSA).
• Analyzing NF-κB activity and phosphorylated MLKL levels in human cancer tissues.

Main Results:

• Genetic knockout of RIPK1, RIPK3, or MLKL significantly reduced cancer cell anchorage-independent growth.
• Knockout cells displayed enhanced radiosensitivity and reduced tumor formation in vivo.
• The necroptosis inhibitor necrosulfonamide (NSA) significantly delayed tumor growth in a xenograft model.
• Necroptotic factors were found to maintain NF-κB activity, and high phosphorylated MLKL levels correlated with poor survival in esophageal and colon cancers.

Conclusions:

• Contrary to established assumptions, necroptotic factors RIPK1, RIPK3, and MLKL actively promote tumor growth.
• Targeting necroptosis, particularly MLKL, represents a promising therapeutic strategy for cancer treatment.
• Understanding the role of necroptosis in NF-κB activation provides mechanistic insight into its pro-tumorigenic effects.